Header Logo

Connection

ZHONGXING LIAO to Lung Neoplasms

Back to Details
This is a "connection" page, showing publications ZHONGXING LIAO has written about Lung Neoplasms.
ZHONGXING LIAO
Connection Strength
6.187
Lung Neoplasms
  1. Treatment-related pulmonary adverse events induced by chemoradiation and Durvalumab affect survival in locally advanced non-small cell lung cancer. Radiother Oncol. 2022 11; 176:149-156.
    View in: PubMed
    Score: 0.170
  2. Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. J Thorac Oncol. 2021 02; 16(2):269-277.
    View in: PubMed
    Score: 0.148
  3. Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):100-107.
    View in: PubMed
    Score: 0.138
  4. Proton therapy for locally advanced non-small cell lung cancer. Br J Radiol. 2020 Mar; 93(1107):20190378.
    View in: PubMed
    Score: 0.137
  5. Validation of Effective Dose as a Better Predictor of Radiation Pneumonitis Risk Than Mean Lung Dose: Secondary Analysis of a Randomized Trial. Int J Radiat Oncol Biol Phys. 2019 02 01; 103(2):403-410.
    View in: PubMed
    Score: 0.128
  6. Patterns of Local-Regional Failure After Intensity Modulated Radiation Therapy or Passive Scattering Proton Therapy With Concurrent Chemotherapy for Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2019 01 01; 103(1):123-131.
    View in: PubMed
    Score: 0.128
  7. Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer. Lung Cancer. 2018 08; 122:60-66.
    View in: PubMed
    Score: 0.125
  8. Reply to R. Rengan et al. J Clin Oncol. 2018 07 01; 36(19):2004-2005.
    View in: PubMed
    Score: 0.125
  9. Future of Protons Depends on Precision. J Clin Oncol. 2018 07 01; 36(19):2002.
    View in: PubMed
    Score: 0.125
  10. Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. Cancer Med. 2018 06; 7(6):2247-2255.
    View in: PubMed
    Score: 0.125
  11. Clinical and Dosimetric Factors Predicting Grade =2 Radiation Pneumonitis After Postoperative Radiotherapy for Patients With Non-Small Cell Lung Carcinoma. Int J Radiat Oncol Biol Phys. 2018 07 15; 101(4):919-926.
    View in: PubMed
    Score: 0.124
  12. Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors? Semin Radiat Oncol. 2018 04; 28(2):114-124.
    View in: PubMed
    Score: 0.124
  13. Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 06 20; 36(18):1813-1822.
    View in: PubMed
    Score: 0.122
  14. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2018 03 01; 100(3):730-737.
    View in: PubMed
    Score: 0.121
  15. Radiation Dose, Local Disease Progression, and Overall Survival in Patients With Inoperable Non-Small Cell Lung Cancer After Concurrent Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018 02 01; 100(2):452-461.
    View in: PubMed
    Score: 0.120
  16. Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer. Oncotarget. 2017 Jun 27; 8(26):43080-43090.
    View in: PubMed
    Score: 0.118
  17. Incidence and Predictors of Pericardial Effusion After Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2017 09 01; 99(1):70-79.
    View in: PubMed
    Score: 0.117
  18. Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
    View in: PubMed
    Score: 0.107
  19. Association between white blood cell count following radiation therapy with radiation pneumonitis in non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Feb 01; 88(2):319-25.
    View in: PubMed
    Score: 0.093
  20. Associations between single-nucleotide polymorphisms in the PI3K-PTEN-AKT-mTOR pathway and increased risk of brain metastasis in patients with non-small cell lung cancer. Clin Cancer Res. 2013 Nov 15; 19(22):6252-60.
    View in: PubMed
    Score: 0.091
  21. Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Apr 01; 85(5):1332-9.
    View in: PubMed
    Score: 0.087
  22. Predictors of high-grade esophagitis after definitive three-dimensional conformal therapy, intensity-modulated radiation therapy, or proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Nov 15; 84(4):1010-6.
    View in: PubMed
    Score: 0.084
  23. Change in diffusing capacity after radiation as an objective measure for grading radiation pneumonitis in patients treated for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 01; 83(5):1573-9.
    View in: PubMed
    Score: 0.084
  24. Predicting pneumonitis risk: a dosimetric alternative to mean lung dose. Int J Radiat Oncol Biol Phys. 2013 Feb 01; 85(2):522-7.
    View in: PubMed
    Score: 0.082
  25. Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. Int J Radiat Oncol Biol Phys. 2013 Jan 01; 85(1):251-7.
    View in: PubMed
    Score: 0.082
  26. Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e61-7.
    View in: PubMed
    Score: 0.082
  27. Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, or proton beam therapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2012 Jul 15; 83(4):e537-43.
    View in: PubMed
    Score: 0.082
  28. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012 May 01; 83(1):332-9.
    View in: PubMed
    Score: 0.080
  29. Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy. Radiother Oncol. 2011 Nov; 101(2):271-7.
    View in: PubMed
    Score: 0.079
  30. Status of particle therapy for lung cancer. Acta Oncol. 2011 Aug; 50(6):745-56.
    View in: PubMed
    Score: 0.078
  31. Huachansu, containing cardiac glycosides, enhances radiosensitivity of human lung cancer cells. Anticancer Res. 2011 Jun; 31(6):2141-8.
    View in: PubMed
    Score: 0.077
  32. Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2010 Aug 16; 10:431.
    View in: PubMed
    Score: 0.073
  33. Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2010 Mar 01; 76(3):775-81.
    View in: PubMed
    Score: 0.067
  34. A phase I clinical trial of thoracic radiotherapy and concurrent celecoxib for patients with unfavorable performance status inoperable/unresectable non-small cell lung cancer. Clin Cancer Res. 2005 May 01; 11(9):3342-8.
    View in: PubMed
    Score: 0.051
  35. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Clin Lung Cancer. 2024 Nov; 25(7):624-633.e2.
    View in: PubMed
    Score: 0.048
  36. COX-2 and its inhibition as a molecular target in the prevention and treatment of lung cancer. Expert Rev Anticancer Ther. 2004 Aug; 4(4):543-60.
    View in: PubMed
    Score: 0.048
  37. Survival outcomes and toxicity of adjuvant immunotherapy after definitive concurrent chemotherapy with proton beam radiation therapy for patients with inoperable locally advanced non-small cell lung carcinoma. Radiother Oncol. 2024 04; 193:110121.
    View in: PubMed
    Score: 0.046
  38. Deep learning-based automatic segmentation of cardiac substructures for lung cancers. Radiother Oncol. 2024 02; 191:110061.
    View in: PubMed
    Score: 0.046
  39. Quantifying the Effect of 4-Dimensional Computed Tomography-Based Deformable Dose Accumulation on Representing Radiation Damage for Patients with Locally Advanced Non-Small Cell Lung Cancer Treated with Standard-Fractionated Intensity-Modulated Radiation Therapy. Int J Radiat Oncol Biol Phys. 2024 Jan 01; 118(1):231-241.
    View in: PubMed
    Score: 0.045
  40. Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol. 2003 Aug; 26(4):S85-91.
    View in: PubMed
    Score: 0.045
  41. Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet. 2023 09 09; 402(10405):871-881.
    View in: PubMed
    Score: 0.045
  42. Benchmarking Outcomes for Molecularly Characterized Synchronous Oligometastatic Non-Small-Cell Lung Cancer Reveals EGFR Mutations to Be Associated With Longer Overall Survival. JCO Precis Oncol. 2023 01; 7:e2200540.
    View in: PubMed
    Score: 0.043
  43. Final efficacy outcomes of atezolizumab with chemoradiation for unresectable NSCLC: The phase II DETERRED trial. Lung Cancer. 2022 Dec; 174:112-117.
    View in: PubMed
    Score: 0.043
  44. Optimization of mesh generation for geometric accuracy, robustness, and efficiency of biomechanical-model-based deformable image registration. Med Phys. 2023 Jan; 50(1):323-329.
    View in: PubMed
    Score: 0.042
  45. Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2002 Jul 01; 53(3):558-65.
    View in: PubMed
    Score: 0.042
  46. Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. Lancet Oncol. 2021 10; 22(10):1448-1457.
    View in: PubMed
    Score: 0.039
  47. Geometric and dosimetric accuracy of deformable image registration between average-intensity images for 4DCT-based adaptive radiotherapy for non-small cell lung cancer. J Appl Clin Med Phys. 2021 Aug; 22(8):156-167.
    View in: PubMed
    Score: 0.039
  48. Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-small-cell Lung Cancer. Clin Lung Cancer. 2021 09; 22(5):e745-e755.
    View in: PubMed
    Score: 0.038
  49. New Data-Driven Gated PET/CT Free of Misregistration Artifacts. Int J Radiat Oncol Biol Phys. 2021 04 01; 109(5):1638-1646.
    View in: PubMed
    Score: 0.037
  50. Associations Between Spirituality, Mindfulness, and Psychological Symptoms Among Advanced Lung Cancer Patients and Their Spousal Caregivers. J Pain Symptom Manage. 2021 05; 61(5):898-908.e1.
    View in: PubMed
    Score: 0.037
  51. A Mindfulness-Based Intervention as a Supportive Care Strategy for Patients with Metastatic Non-Small Cell Lung Cancer and Their Spouses: Results of a Three-Arm Pilot Randomized Controlled Trial. Oncologist. 2020 11; 25(11):e1794-e1802.
    View in: PubMed
    Score: 0.037
  52. Development and application of an elastic net logistic regression model to investigate the impact of cardiac substructure dose on radiation-induced pericardial effusion in patients with NSCLC. Acta Oncol. 2020 Oct; 59(10):1193-1200.
    View in: PubMed
    Score: 0.036
  53. Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. Clin Lung Cancer. 2021 05; 22(3):225-233.e7.
    View in: PubMed
    Score: 0.036
  54. Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer. J Thorac Oncol. 2020 10; 15(10):1682-1690.
    View in: PubMed
    Score: 0.036
  55. Giant Circulating Cancer-Associated Macrophage-Like Cells Are Associated With Disease Recurrence and Survival in Non-Small-Cell Lung Cancer Treated With Chemoradiation and Atezolizumab. Clin Lung Cancer. 2021 05; 22(3):e451-e465.
    View in: PubMed
    Score: 0.036
  56. Lyman-Kutcher-Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. Radiother Oncol. 2020 05; 146:200-204.
    View in: PubMed
    Score: 0.036
  57. Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. JAMA Netw Open. 2020 04 01; 3(4):e203277.
    View in: PubMed
    Score: 0.036
  58. Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. Head Neck. 2020 08; 42(8):1939-1953.
    View in: PubMed
    Score: 0.035
  59. Stereotactic ablative radiation therapy for pulmonary metastases: Improving overall survival and identifying subgroups at high risk of local failure. Radiother Oncol. 2020 04; 145:178-185.
    View in: PubMed
    Score: 0.035
  60. Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020 07; 21(4):e294-e301.
    View in: PubMed
    Score: 0.035
  61. Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. J Thorac Oncol. 2020 02; 15(2):248-257.
    View in: PubMed
    Score: 0.035
  62. Immune and Circulating Tumor DNA Profiling After Radiation Treatment for Oligometastatic Non-Small Cell Lung Cancer: Translational Correlatives from a Mature Randomized Phase II Trial. Int J Radiat Oncol Biol Phys. 2020 02 01; 106(2):349-357.
    View in: PubMed
    Score: 0.035
  63. Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. Radiother Oncol. 2019 07; 136:136-142.
    View in: PubMed
    Score: 0.033
  64. Dyadic yoga program for patients undergoing thoracic radiotherapy and their family caregivers: Results of a pilot randomized controlled trial. Psychooncology. 2019 03; 28(3):615-621.
    View in: PubMed
    Score: 0.033
  65. Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. JAMA Netw Open. 2018 08 03; 1(4):e181390.
    View in: PubMed
    Score: 0.032
  66. Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res. 2018 06; 27(6):1563-1570.
    View in: PubMed
    Score: 0.031
  67. Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2018 07 01; 101(3):558-563.
    View in: PubMed
    Score: 0.031
  68. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiother Oncol. 2017 11; 125(2):325-330.
    View in: PubMed
    Score: 0.030
  69. Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer: Final Results of a Phase 2 Study. JAMA Oncol. 2017 08 10; 3(8):e172032.
    View in: PubMed
    Score: 0.030
  70. Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clin Exp Metastasis. 2017 06; 34(5):315-322.
    View in: PubMed
    Score: 0.030
  71. Differences in Normal Tissue Response in the Esophagus Between Proton and Photon Radiation Therapy for Non-Small Cell Lung Cancer Using In?Vivo Imaging Biomarkers. Int J Radiat Oncol Biol Phys. 2017 11 15; 99(4):1013-1020.
    View in: PubMed
    Score: 0.029
  72. Delta-radiomics features for the prediction of patient outcomes in non-small cell lung cancer. Sci Rep. 2017 04 03; 7(1):588.
    View in: PubMed
    Score: 0.029
  73. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
    View in: PubMed
    Score: 0.029
  74. Outcomes and toxicity following high-dose radiation therapy in 15 fractions for non-small cell lung cancer. Pract Radiat Oncol. 2017 Nov - Dec; 7(6):433-441.
    View in: PubMed
    Score: 0.029
  75. Impact of heart and lung dose on early survival in patients with non-small cell lung cancer treated with chemoradiation. Radiother Oncol. 2016 06; 119(3):495-500.
    View in: PubMed
    Score: 0.027
  76. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta Oncol. 2016 Aug; 55(8):1022-8.
    View in: PubMed
    Score: 0.027
  77. NSCLC tumor shrinkage prediction using quantitative image features. Comput Med Imaging Graph. 2016 Apr; 49:29-36.
    View in: PubMed
    Score: 0.026
  78. Potential Use of (18)F-fluorodeoxyglucose Positron Emission Tomography-Based Quantitative Imaging Features for Guiding Dose Escalation in Stage III Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2016 Feb 01; 94(2):368-76.
    View in: PubMed
    Score: 0.026
  79. Lung Size and the Risk of Radiation Pneumonitis. Int J Radiat Oncol Biol Phys. 2016 Feb 01; 94(2):377-84.
    View in: PubMed
    Score: 0.026
  80. Stage III Non-Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors. Radiology. 2016 Jan; 278(1):214-22.
    View in: PubMed
    Score: 0.026
  81. Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. Radiother Oncol. 2015 Jun; 115(3):367-72.
    View in: PubMed
    Score: 0.025
  82. Vivekananda Yoga Program for Patients With Advanced Lung Cancer and Their Family Caregivers. Integr Cancer Ther. 2015 Sep; 14(5):446-51.
    View in: PubMed
    Score: 0.025
  83. Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. Radiother Oncol. 2015 Mar; 114(3):367-72.
    View in: PubMed
    Score: 0.025
  84. Early experience with intensity modulated proton therapy for lung-intact mesothelioma: A case series. Pract Radiat Oncol. 2015 Jul-Aug; 5(4):e345-53.
    View in: PubMed
    Score: 0.025
  85. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. Radiother Oncol. 2014 Dec; 113(3):379-84.
    View in: PubMed
    Score: 0.025
  86. Hemithoracic intensity modulated radiation therapy after pleurectomy/decortication for malignant pleural mesothelioma: toxicity, patterns of failure, and a matched survival analysis. Int J Radiat Oncol Biol Phys. 2015 Jan 01; 91(1):149-56.
    View in: PubMed
    Score: 0.024
  87. Use of simultaneous radiation boost achieves high control rates in patients with non-small-cell lung cancer who are not candidates for surgery or conventional chemoradiation. Clin Lung Cancer. 2015 Mar; 16(2):156-63.
    View in: PubMed
    Score: 0.024
  88. Clinical implementation of intensity modulated proton therapy for thoracic malignancies. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):809-18.
    View in: PubMed
    Score: 0.024
  89. Prognostic value and reproducibility of pretreatment CT texture features in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):834-42.
    View in: PubMed
    Score: 0.024
  90. Definitive reirradiation for locoregionally recurrent non-small cell lung cancer with proton beam therapy or intensity modulated radiation therapy: predictors of high-grade toxicity and survival outcomes. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):819-27.
    View in: PubMed
    Score: 0.024
  91. Impact of respiratory motion on worst-case scenario optimized intensity modulated proton therapy for lung cancers. Pract Radiat Oncol. 2015 Mar-Apr; 5(2):e77-86.
    View in: PubMed
    Score: 0.024
  92. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front-line chemotherapy. Int J Radiat Oncol Biol Phys. 2014 Nov 15; 90(4):850-7.
    View in: PubMed
    Score: 0.024
  93. Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. Pract Radiat Oncol. 2014 Nov-Dec; 4(6):e259-68.
    View in: PubMed
    Score: 0.024
  94. Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014 Aug; 112(2):256-61.
    View in: PubMed
    Score: 0.024
  95. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014 Aug 01; 89(5):1084-1091.
    View in: PubMed
    Score: 0.024
  96. Couple-based Tibetan yoga program for lung cancer patients and their caregivers. Psychooncology. 2015 Jan; 24(1):117-20.
    View in: PubMed
    Score: 0.024
  97. Acute phase response before treatment predicts radiation esophagitis in non-small cell lung cancer. Radiother Oncol. 2014 Mar; 110(3):493-8.
    View in: PubMed
    Score: 0.023
  98. On the interplay effects with proton scanning beams in stage III lung cancer. Med Phys. 2014 Feb; 41(2):021721.
    View in: PubMed
    Score: 0.023
  99. Patient-specific quantification of respiratory motion-induced dose uncertainty for step-and-shoot IMRT of lung cancer. Med Phys. 2013 Dec; 40(12):121712.
    View in: PubMed
    Score: 0.023
  100. Effects of respiratory motion on passively scattered proton therapy versus intensity modulated photon therapy for stage III lung cancer: are proton plans more sensitive to breathing motion? Int J Radiat Oncol Biol Phys. 2013 Nov 01; 87(3):576-82.
    View in: PubMed
    Score: 0.023
  101. Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiother Oncol. 2013 Oct; 109(1):38-44.
    View in: PubMed
    Score: 0.023
  102. Comparison of 2 common radiation therapy techniques for definitive treatment of small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Sep 01; 87(1):139-47.
    View in: PubMed
    Score: 0.023
  103. Is there an impact of heart exposure on the incidence of radiation pneumonitis? Analysis of data from a large clinical cohort. Acta Oncol. 2014 May; 53(5):590-6.
    View in: PubMed
    Score: 0.023
  104. Phase 1 study of dose escalation in hypofractionated proton beam therapy for non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):665-70.
    View in: PubMed
    Score: 0.022
  105. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol. 2013 Mar 01; 31(7):895-902.
    View in: PubMed
    Score: 0.022
  106. Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Med Dosim. 2013; 38(4):442-447.
    View in: PubMed
    Score: 0.022
  107. Prescribing radiation dose to lung cancer patients based on personalized toxicity estimates. J Thorac Oncol. 2012 Nov; 7(11):1676-82.
    View in: PubMed
    Score: 0.021
  108. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. Radiat Oncol. 2012 Sep 10; 7:152.
    View in: PubMed
    Score: 0.021
  109. Automated volumetric modulated Arc therapy treatment planning for stage III lung cancer: how does it compare with intensity-modulated radio therapy? Int J Radiat Oncol Biol Phys. 2012 Sep 01; 84(1):e69-76.
    View in: PubMed
    Score: 0.021
  110. Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Chin Med J (Engl). 2011 Dec; 124(24):4132-7.
    View in: PubMed
    Score: 0.020
  111. TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. BMC Cancer. 2011 Oct 14; 11:447.
    View in: PubMed
    Score: 0.020
  112. Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. Cancer. 2012 Jan 15; 118(2):528-35.
    View in: PubMed
    Score: 0.019
  113. Investigation of the relationship between gross tumor volume location and pneumonitis rates using a large clinical database of non-small-cell lung cancer patients. Int J Radiat Oncol Biol Phys. 2012 Apr 01; 82(5):1650-8.
    View in: PubMed
    Score: 0.019
  114. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist. 2011; 16(2):217-27.
    View in: PubMed
    Score: 0.019
  115. Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. Cancer. 2011 Jul 01; 117(13):3004-13.
    View in: PubMed
    Score: 0.019
  116. Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer. PLoS One. 2010 Aug 25; 5(8):e12402.
    View in: PubMed
    Score: 0.018
  117. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009 Nov 15; 115(22):5309-18.
    View in: PubMed
    Score: 0.017
  118. Patterns of cardiac perfusion abnormalities after chemoradiotherapy in patients with lung cancer. J Thorac Oncol. 2009 Feb; 4(2):179-84.
    View in: PubMed
    Score: 0.016
  119. Stereotactic body radiation therapy in centrally and superiorly located stage I or isolated recurrent non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 15; 72(4):967-71.
    View in: PubMed
    Score: 0.016
  120. Effects of respiration-averaged computed tomography on positron emission tomography/computed tomography quantification and its potential impact on gross tumor volume delineation. Int J Radiat Oncol Biol Phys. 2008 Jul 01; 71(3):890-9.
    View in: PubMed
    Score: 0.016
  121. Impact of cancer therapy on clonal hematopoiesis mutations and subsequent clinical outcomes. Blood Adv. 2024 10 08; 8(19):5215-5224.
    View in: PubMed
    Score: 0.012
  122. Equivalent outcome of patients with clinical Stage IIIA non-small-cell lung cancer treated with concurrent chemoradiation compared with induction chemotherapy followed by surgical resection. Int J Radiat Oncol Biol Phys. 2004 Jan 01; 58(1):204-12.
    View in: PubMed
    Score: 0.012
  123. Postoperative radiotherapy increases locoregional control of patients with stage IIIA non-small-cell lung cancer treated with induction chemotherapy followed by surgery. Int J Radiat Oncol Biol Phys. 2003 Jul 01; 56(3):616-25.
    View in: PubMed
    Score: 0.011
  124. Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 2003 Jan; 9(1):93-101.
    View in: PubMed
    Score: 0.011
  125. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results. Semin Radiat Oncol. 2002 Jan; 12(1 Suppl 1):46-9.
    View in: PubMed
    Score: 0.010
  126. Respiratory-driven lung tumor motion is independent of tumor size, tumor location, and pulmonary function. Int J Radiat Oncol Biol Phys. 2001 Sep 01; 51(1):62-8.
    View in: PubMed
    Score: 0.010
  127. Automatic segmentation of cardiac substructures from noncontrast CT images: accurate enough for dosimetric analysis? Acta Oncol. 2019 Jan; 58(1):81-87.
    View in: PubMed
    Score: 0.008
  128. The utility of quantitative CT radiomics features for improved prediction of radiation pneumonitis. Med Phys. 2018 Nov; 45(11):5317-5324.
    View in: PubMed
    Score: 0.008
  129. Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. Pract Radiat Oncol. 2017 May - Jun; 7(3):e195-e203.
    View in: PubMed
    Score: 0.007
  130. (18)F-Fluorodeoxyglucose Positron Emission Tomography Can Quantify and Predict Esophageal Injury During Radiation Therapy. Int J Radiat Oncol Biol Phys. 2016 11 01; 96(3):670-8.
    View in: PubMed
    Score: 0.007
  131. Analysis of esophageal-sparing treatment plans for patients with high-grade esophagitis. J Appl Clin Med Phys. 2013 Jul 08; 14(4):4248.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.